Market Overview
Size, analog mix, and diabetes burden
- Brevintel analysis values the insulin market at USD 29.2 billion in 2025 ($29.2B / USD 29.2 billion), rising from USD 30.7 billion in 2026 to USD 41.4 billion by 2035 ($41.4B) at a 3.4% CAGR (2026-2035).
- Insulin analog generated USD 22.3 billion in 2025 and remains the commercial center because formulations alter onset, duration, or peak activity versus conventional human insulin.
- Novo Nordisk led with over 45.3% market share in 2025; Novo Nordisk, Sanofi, and Eli Lilly and Company collectively held a market share of 90% in 2025.
- The International Diabetes Federation estimated that 537 million adults aged 20–79 were living with diabetes in 2021, with totals projected at 643 million by 2030 and 783 million by 2045; 45% of adults with diabetes were undiagnosed.
- NCD Risk Factor Collaboration estimated that more than one billion people were living with obesity in 2022, including 879 million adults and 159 million children and adolescents.
- In the United States, 38.4 million people had diabetes in 2021, including 8.7 million undiagnosed cases, and the country accounted for USD 10.6 billion of insulin revenue in 2025.
- Demand cannot be deferred for people with type 1 diabetes and often becomes necessary as type 2 diabetes progresses beyond non-insulin treatment.
- Value capture remains more concentrated than patient demand: a three-company group controlling more than 90% of market value can defend analog pools through manufacturing scale, device compatibility, and payer contracting.
Market Dynamics
Diabetes burden, delivery systems, and affordability
- The IDF projects a 46% increase in adults living with diabetes between 2021 and 2045, exceeding expected global population growth over the same period.
- The IDF T1D Index estimated that 1.8 million children and adolescents under age 20 were living with type 1 diabetes in 2025, while the global population across all ages is projected to reach 14.7 million by 2040.
- An estimated one in six live births was affected by hyperglycemia in pregnancy in 2021, with gestational diabetes accounting for most cases and insulin remaining an option because it does not cross the placenta.
- The FDA authorized CamAPS FX for people with type 1 diabetes aged two years and older in May 2024; Insulet reported that its SECURE-T2D pivotal trial supported expanded use of Omnipod 5 in type 2 diabetes.
- The Inflation Reduction Act capped Medicare Part D patient out-of-pocket spending for covered insulin products at USD 35 per month, while the INSULIN Act and Affordable Insulin Now Act propose broader affordability provisions.
- Eli Lilly announced in March 2023 that it would reduce the list prices of Humalog and Humulin by 70% and expand its insulin affordability program.
- The IDF estimated global diabetes-related health expenditure at USD 966 billion in 2021, yet high aggregate spending does not ensure consistent access where coverage or cold-chain distribution is limited.
- Type 1 diabetes accounted for 75.2% of market value in 2025 and has no substitute for exogenous insulin; non-insulin therapies may delay basal initiation in type 2 diabetes without removing insulin's role in advanced disease.
Segmentation Analysis
Type, product, application, and distribution channel
- The market is segmented by type, product, application, and distribution channel.
- Insulin analog generated USD 22.3 billion in 2025; human insulin remains important where affordability and public procurement favor lower-cost options.
- The FDA's February 2025 approval of Merilog as the first rapid-acting insulin biosimilar in the U.S. extends biosimilar competition beyond the long-acting category.
- Long-acting insulin held 45.3% of market value in 2025 as the typical initial insulin regimen for many people with progressive type 2 diabetes and as basal coverage in type 1 diabetes.
- Rapid-acting insulin accounted for 31.3% of revenue in 2025, reinforced by basal-bolus regimens and automated insulin delivery systems.
- Type 1 diabetes mellitus represented 75.2% of market value in 2025 and is projected to grow at a 3.3% CAGR through 2035; type 2 diabetes mellitus is projected to grow at a faster 3.9% CAGR.
- Hospital pharmacies are the leading distribution channel and are projected to reach USD 21.5 billion by 2035, concentrating initiation, titration, and tendered supply.
- Retail pharmacies remain essential for outpatient refills as biosimilar substitution expands; online pharmacies depend on telehealth, reimbursement, and temperature-controlled delivery.
Regional Outlook
North America, Europe, Asia Pacific, Latin America, and Middle East and Africa
- North America accounted for 40.1% of global insulin revenue in 2025, and the U.S. market was valued at USD 10.6 billion, with 38.4 million people with diabetes in 2021 including 8.7 million undiagnosed cases.
- Medicare's USD 35 monthly insulin cap and manufacturer price reductions are narrowing the gap between list-price practices and patient affordability across the United States.
- Europe is projected to grow at a 3.7% CAGR through 2035, with Germany, the UK, France, Italy, Spain, and the Netherlands shaped by reimbursement systems and biosimilar uptake.
- Sanofi announced in December 2024 that it would invest EUR 1 billion in an insulin production base in Beijing, its fourth production and supply base in China.
- Biocon Biologics' November 2022 acquisition of Viatris' global biosimilars business provided commercial infrastructure across advanced and emerging markets.
- IDF estimates identified more than 16 million adults with diabetes in Brazil in 2021, including approximately 7.7 million undiagnosed people.
- Saudi Arabia had an adult diabetes prevalence of 18.2% in 2021, projected to reach 24.3% by 2026, supporting analog uptake where funded access exists.
- Geography is becoming the clearest determinant of insulin revenue quality: North America's 40.1% share in 2025 is pressured by affordability policy, while China's volume-based purchasing favors domestic scale.
Competitive Landscape
Structure and recent developments
- Novo Nordisk, Eli Lilly, and Sanofi collectively account for more than 90% of global insulin market value through analog brands, biologics manufacturing, and device compatibility.
- Adocia is developing differentiated insulin formulations through its BioChaperone platform, including a collaboration with Tonghua Dongbao on BioChaperone Lispro in China.
- In December 2024, Adocia and Tonghua Dongbao completed final dosing in a Phase 3 study of BioChaperone Lispro in China, associated with a USD 10 million payment to Adocia.
- In February 2025 the FDA approved Merilog, insulin-aspart-szjj, as the first rapid-acting insulin biosimilar in the U.S., biosimilar to NovoLog in prefilled pen and multiple-dose vial presentations.
- Eli Lilly and Company's 2023 list-price reductions of 70% on Humalog and Humulin demonstrate how access pressures are changing originator pricing strategy.
- Gan & Lee Pharmaceuticals and Tonghua Dongbao Pharmaceutical are positioned where domestic supply and tender pricing influence purchasing in China.
Integrated producers
- Novo Nordisk
- Sanofi
- Eli Lilly and Company
Specialty suppliers
- Adocia
- Biocon Biologics
- Boehringer Ingelheim
- Gan & Lee Pharmaceuticals
- Tonghua Dongbao Pharmaceutical
- Gland Pharma
- Julphar